SD Biotechnologies KRX:217480KOSDAQ
에스디생명공학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked9since Sep 11
In Q2 2026, SD Biotechnologies reported revenue of ₩6.3bn, down 19.3% year on year, and an operating loss of ₩1.4bn. SD Biotechnologies (에스디생명공학) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Split / consolidation 4 quarters of losses Delisting / halt risk Screener
SD Biotechnologies quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.3bn | -19.3% | −₩1.4bn margin −22.1% | −₩875m |
| Q1 2026 | ₩6.1bn | -33.0% | −₩1.1bn margin −17.5% | −₩1.2bn |
| Q4 2025 derived | ₩6.3bn | -4.2% | −₩1.6bn margin −24.5% | −₩3.0bn |
| Q3 2025 | ₩6.9bn | -15.4% | −₩1.7bn margin −25.4% | −₩1.9bn |
| Q2 2025 | ₩7.8bn | -19.5% | −₩1.9bn margin −24.0% | −₩1.3bn |
| Q1 2025 | ₩9.1bn | -9.8% | −₩1.2bn margin −12.7% | −₩1.3bn |
| Q4 2024 derived | ₩6.6bn | +84.8% | −₩3.5bn margin −52.6% | −₩5.3bn |
| Q3 2024 | ₩8.1bn | -31.2% | −₩2.2bn margin −26.7% | −₩3.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SD Biotechnologies top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest SD Biotechnologies news Korean headlines
-
대원제약 자회사 에스디생명공학, 상장폐지 법정 공방
1 more on this story · 1 outlets
- 대원제약 자회사 에스디생명공학, 상장폐지 법정 공방조선일보 · Oct 8 18:40